The shares of distinguished pharmaceutical firms gained as much as 4 p.c in immediately’s buying and selling session after the corporate signed definitive agreements with world funding agency KKR to accumulate a controlling stake in JB Chemical compounds & Prescribed drugs value Rs 25,689 crores on a completely diluted foundation.
With a market capitalization of Rs 1.13 lakh crore, the shares of Torrent Prescribed drugs Ltd had been buying and selling at Rs 3,350.75 per share, growing round 0.19 p.c as in comparison with the earlier closing worth of Rs 3,344.40 apiece.
The shares of Torrent Prescribed drugs Ltd have seen optimistic motion after it signed definitive agreements to accumulate a controlling stake in JB Chemical compounds & Prescribed drugs from KKR at an fairness valuation of Rs 25,689 crore (absolutely diluted). The deal might be adopted by a merger of each firms, boosting Torrent’s market place and product portfolio.
Additional, Torrent Pharma will purchase a 46.39 p.c stake in JB Pharma for Rs 11,917 crore (₹1,600 per share) by way of a Share Buy Settlement with KKR. A compulsory open provide will comply with to purchase as much as 26 p.c from public shareholders at Rs 1,639.18 per share. Torrent additionally goals to buy 2.80 p.c fairness from JB Pharma staff on the identical worth.
The acquisition presents Torrent Pharma a fast-growing India franchise with robust continual section manufacturers and entry to new areas like ophthalmology. It enhances Torrent’s IPM market share, allows operational synergies, and diversifies its platform by CDMO entry. The deal additionally strengthens its world footprint and helps scalable worldwide growth.
Additionally learn: EV shares to look at as India’s EV market set to hit $114 billion by 2029, rising at 66.5% CAGR
Moreover, Torrent Pharma and JB Pharma will merge by a scheme of association permitted by each boards. Below the phrases, JB Pharma shareholders will obtain 51 Torrent shares for each 100 JB Pharma shares held. The share swap goals to streamline operations, unlock synergies, and strengthen Torrent’s presence within the home and worldwide pharmaceutical markets.
Furthermore, J.B. Chemical compounds & Prescribed drugs Ltd, a publicly listed firm, makes a speciality of manufacturing and advertising and marketing a broad vary of pharmaceutical formulations. As of March 31, 2025, it reported a consolidated turnover of ₹3,918 crore and a web value of ₹3,433.32 crore. The corporate’s robust financials make it a strategic match for Torrent Pharma’s progress ambitions.
“We’re happy to have on board the JB Pharma heritage and construct on the platform for the long run. Torrent’s deep India presence and JB Pharma’s fast-growing India enterprise, mixed with the CDMO and worldwide footprint, provide immense potential to scale each income and profitability. This strategic alignment furthers our purpose of strengthening our presence within the Indian pharma market and builds a bigger, diversified world presence. Furthermore, the CDMO platform offers a brand new long-term avenue of progress for Torrent,” mentioned Samir Mehta, Government Chairman, Torrent.
Trying ahead to the corporate’s monetary efficiency, income elevated by 8 p.c from Rs 2,745 crore in Q4FY24 to Rs 2,959 crore in Q4FY25. Additional, throughout the identical time-frame, web revenue elevated by 11 p.c from Rs 449 crore to Rs 498 crore.
Torrent Prescribed drugs Restricted is an India-based pharmaceutical firm. The Firm is targeted on numerous therapeutic segments, akin to cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), nutritional vitamins, minerals, vitamins (VMN), anti-diabetes (AD), ache, gynecology, and dermatology.
Written by Abhishek Singh
Disclaimer
The views and funding suggestions expressed by funding consultants/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer aren’t responsible for any losses induced on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
